Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

anagrelide

Known as: Anagrelida, Anagrelidum, anagrelide [Chemical/Ingredient] 
A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-ABL1-negative myeloproliferative… Expand
  • table 1
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
High platelet counts in essential thrombocythemia (ET) can be effectively lowered by treatment with either anagrelide or… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but is seen in only half those… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
To define the mechanism by which anagrelide normalizes the platelet count in essential thrombocythemia, we studied in vivo… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Anagrelide is a novel platelet-lowering agent that has recently been approved for use in essential thrombocythemia (ET) and… Expand
  • table 1
  • table 3
Is this relevant?
Review
1997
Review
1997
This report suggests modest changes in the criteria used for the diagnosis of ET and allows tentative recommendations concerning… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Anagrelide, an inhibitor of platelet aggregation, decreases the number of platelets in normal subjects and in patients with… Expand
Is this relevant?
Highly Cited
1992
Highly Cited
1992
PURPOSE To evaluate the safety and efficacy of anagrelide when used to reduce platelet counts in patients with thrombocytosis… Expand
Is this relevant?
Highly Cited
1988
Highly Cited
1988
Anagrelide is a member of the imidazo (2,1-b) quinazolin-2-one series of compounds, with a powerful antiaggregating effect on… Expand
Is this relevant?